Ignite Creation Date:
2024-10-25 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06609239
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-20
Brief Title:
Long-term Safety and Efficacy Evaluation of Lunsekimig SAR443765 in Adult Participants With Moderatetosevere Asthma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AIRPHRODITE
Brief Summary:
This is a phase 2 open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with moderate-to-severe asthma who have previously completed the parent study After completion of the parent study eligible participants will be offered the opportunity to participate in the long-term extension LTE study with lunsekimig
The study duration will be up to 100 weeks with a treatment duration being up to 96 weeks
The study duration will be up to 100 weeks with a treatment duration being up to 96 weeks
Detailed Description:
Enter Intervention Groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None